@entity6927 -Adrenoreceptors are thought to be involved in prostate smooth muscle contractions and could hence play a role in the dynamic component of intravesical obstruction associated with symptomatic BPH. Consequently, since the mid-eighties alpha receptor blocking agents have been used for the treatment of BPH. Non-selective alpha blockers are usually associated with systemic side-effects which resulted in an exclusion or withdrawal of many @entity1 from this form of treatment. With the availability of so-called uroselective alpha blockers the management picture has changed since it was anticipated that these compounds cause lesser side-effects with at least the same, or even better, efficacy. Comparative clinical studies are essential for determining the eventual advantages of the uroselective @entity6927 -antagonists and a large number of such studies have been performed worldwide studying the various available compounds. European studies with @entity7477 showed clear superiority of the drug over the placebo while causing only limited side-effects. Various other studies using alpha-blocking agents such as @entity16427 , @entity9940 and @entity31503 yielded identical results. Especially with @entity9940 and @entity31503 , the side-effects were comparable with those encountered in the placebo group. About 7% of the @entity1 using @entity9940 experienced @entity2754 in one study which did not occur in the @entity31503 studies. Important studies in Europe have also investigated the value of a combination of an alpha blocker with a @entity10831 inhibitor. Comparable studies in which both @entity31503 and @entity16427 were combined with the @entity10831 inhibitor Proscar have shown that a combination is not superior to a blocker monotherapy and especially in the ALFIN study the results show that @entity31503 monotherapy is superior to Proscar in the management of symptomatic BPH. European studies have evaluated Quality of Life, sexuality as well as socio-economical outcome of the treatment with @entity6927 receptor antagonists. These studies completed the spectrum of clinical research in Europe in the important field of management of symptomatic BPH with uroselective @entity6927 antagonists.

Clinical experience in Europe with uroselective XXXX -antagonists.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity7477 :: ('MESH:C041226', 'Chemical') :: ['terazosin'] @entity16427 :: ('MESH:D017292', 'Chemical') :: ['doxazosin'] @entity10831 :: ('6715', 'Gene') :: ['5alpha-reductase'] @entity31503 :: ('MESH:C047638', 'Chemical') :: ['alfuzosin'] @entity2754 :: ('MESH:D061686', 'Disease') :: ['retrograde ejaculation'] @entity9940 :: ('MESH:C088482', 'Chemical') :: ['tamsulosin'] @entity6927 :: ('146', 'Gene') :: ['alpha1']
@entity6927 :: (146,Gene) :: ['alpha1']
